Results from the DANISH Study (Danish Study to Assess the Efficacy of ICDs in Patients with Nonischemic Systolic Heat Failure on Mortality) suggest that, for many patients with dilated cardiomyopathy (DCM), implantable cardioverter defibrillators (ICD) do not increase longevity.
Background 1
Dilated cardiomyopathy (DCM) is a disease of the myocardium characterised by a reduction in left 2 ventricular systolic function and left ventricular dilatation that cannot exclusively be explained by 3 abnormal loading or ischemic injury 1 . It is one of the most common cardiomyopathies, with a 4 predicted incidence of 1 in 400 in the US 2 . Three-year treated mortality rates remain high at 12-20%, 5
with death typically resulting from heart failure (HF) or ventricular arrhythmia manifesting as sudden 6 cardiac death (SCD) [3] [4] [5] [6] [7] . DCM accounts for a substantial proportion of SCD, especially amongst people 7 of working age, with an annual incidence of 2-3% 4, [8] [9] [10] . SCD is unheralded in 40-50% of cases and 8 occurs out-of-hospital in the majority of patients 10, 11 . Implantable cardioverter defibrillators (ICDs) 9 have the ability to promptly recognize and treat ventricular arrhythmias and thus form the 10 cornerstone of SCD prevention. Patients with DCM compared with those with ischemic heart 11 disease (IHD), are typically younger with less co-morbidity and therefore have a lower mortality risk 12 from other causes. They, therefore appear ideal candidates to benefit from ICD therapy. 13 Current guidelines recommend the use of ICDs for the primary prevention of SCD in patients with 14 DCM, New York Heart Association (NYHA) class II-III HF and a left ventricular ejection fraction (LVEF) 15 <35% 12, 13 . However, 4 individual randomized trials in patients with DCM and a LVEF <35% have failed 16 to show a significant reduction in all-cause mortality with ICD therapy, while only 1 demonstrated a 17 a mortality benefit 3, 4, 7 . A more precise risk stratification algorithm is therefore a major unmet need. 18 In this review, we summarize the current evidence for primary prevention ICD implantation in 19 patients with DCM and illustrate the need for improved risk stratification 3, 4, 7, 14 . We discuss 20 strategies and techniques that we expect to be used to improve risk stratification over the next 5-10 21 years by providing more comprehensive disease phenotyping. We review techniques that may 22 improve risk stratification, building from simple clinical variables to more complex imaging 23 techniques and genetic analysis. 24 
25

Primary Prevention ICD Trials in DCM -The Need to Improve the Sensitivity and Specificity of the 1
Current Approach 2
Five trials have investigated the effect of ICD implantation in patients with DCM without a history of 3 cardiac arrest or hemodynamically unstable ventricular arrhythmia ( Table 1 ) [3] [4] [5] [6] [7] . The Cardiomyopathy 4
Trial (CAT) and the Amiodarone vs Implantable Cardioverter-Defibrillator (AMIOVIRT) trial were 5 terminated prematurely due to a low mortality rate and lack of statistical power 5, 6 . The Sudden 6 Cardiac Death in Heart Failure Trial (SCD-HeFT) investigated the effect of primary prevention ICD 7 implantation in patients with ischemic cardiomyopathy or DCM with NYHA class II-III HF and an LVEF 8 <35% 3 . ICD therapy was associated with a reduction in overall mortality across both etiologies (HR 9 0.77; 97.5% CI: 0.62-0.96; p=0.007). 10 The Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) study evaluated 11 the effects of ICD therapy in patients with DCM, HF, a LVEF ≤35% and non-sustained VT or frequent 12 ventricular ectopy 4 . All-cause mortality was not significantly reduced with ICD therapy (HR 0.65; 13 95%CI 0.40-1.1; p=0.08) but a reduction in SCD was observed (HR 0.20; 95%CI 0.06-0.71; p=0.006). 14 Current guidelines on the use of ICDs for the primary prevention of SCD in DCM are based on a 15 meta-analysis of these trials, which demonstrated a reduction in all-cause mortality with ICD therapy 16 (HR 0.74, p=0.02) 12, 14, 15 . 17
Subsequently, the Danish Study to Assess the Efficacy of ICDs in Patients with Non-Ischemic Systolic 18
Heat Failure on Mortality (DANISH) investigated ICD therapy versus optimal medical therapy (OMT) 19 in patients with non-ischemic cardiomyopathy (76% idiopathic, 4% valvular, 11% hypertensive, 9% 20 other), HF, LVEF <35% and N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) >200pg/ml 7 . All-21 cause mortality was not lower in patients with ICDs (HR 0.87; 95% CI: 0.68-1.12; p=0.28); however 22 SCD was reduced (HR 0.50; 95% CI: 0.31-0.82; p=0.005). Overall mortality was less than 5% per year 23 and in the control group, only 1/3 of the deaths were attributed to SCD. Notably, the percentage of 24 patients treated with contemporary OMT was higher than previous trials; 97% were prescribedangiotensin converting enzyme inhibitors or angiotensin receptor blockers and 92% beta-blockers. In 1 addition, 58% of patients in both arms received CRT, including 93% of those with LBBB and a QRS 2 >150ms. CRT alone may reduce SCD risk by improving left ventricular function and preventing 3 bradycardia-triggered lethal arrhythmias. An updated meta-analysis, including data from DANISH, 4 has demonstrated a 23% reduction in all-cause mortality with ICD therapy compared with OMT 5 alone (HR 0.77; 95% CI 0.64-0.91) 16 . 6
Additional interpretation of the trials demonstrates the poor specificity of LVEF-based guidelines. In 7 each of the trials, there was a low incidence of appropriate ICD therapies: 5.1% over 1 year in SCD-8
HeFT, 17.9% over 3 years in DEFINITE and 11.5% over 5.6 years in DANISH 3, 4, 7 . This finding is partially 9 explained by an improved prognosis for many with OMT. Left ventricular reverse remodelling occurs 10 in up to 37% of patients treated with OMT, supporting the importance of postponing risk 11 stratification until after a period of OMT 17 . In DEFINITE, of those with a follow-up LVEF, 12 approximately half had an improvement in LVEF >5% associated with substantially reduced 13 mortality 18 . Another explanation for the low incidence of appropriate therapies is a high residual 14 incidence of death from competing causes; as the risk of non-sudden death increases, the chances of 15 gaining benefit from ICD therapy diminishes. 16 Conversely, it is clear that the sensitivity of LVEF for predicting SCD is poor. Registries of out-of-17 hospital cardiac arrests have demonstrated that the majority of such patients do not have severely 18 reduced LVEF 10, 11 . In the Oregon and Maastricht registries, in those cases with pre-mortem 19 echocardiography, only 20-30% had a low enough LVEF to meet criteria for an ICD 10, 11 . DCM-specific 20 registries have confirmed that, although the overall risk of SCD may be higher in patients with 21
severely reduced LVEF, the number with mild or moderate reductions in LVEF is greater and their 22 risk remains significant 19 . Moreover, this group of patients are likely to have lower risks of death 23 from competing causes and less likely to be limited by symptoms. The number of quality-adjusted 24 life years gained from successful ICD therapy may therefore be greater.
The risk of complications and the costs of ICD implantation are also important considerations. 1
Although less common compared with 10 years ago, the incidence of inappropriate shocks is 2 associated with morbidity and reduced quality of life 4, 7, 20, 21 . Early procedure-related complications 3 occur in 4% of cases, while device-related infection complicates 4.9% 7, 21 . As well as worsening 4 outcomes, complications add costs to the considerable expenditure associated with ICDs. It has been 5 estimated that if devices were implanted as recommended, an extra 850,000 patients in the US 6 would be offered ICD implantation, in addition to the 80,000 patients who currently receive them 7 annually, at a total cost of $30 billion 22 . These issues highlight the wider importance of optimizing 8 the selection of patients. 9
In conclusion, current research demonstrates the inadequacy of a risk stratification algorithm based 10 on LVEF and illustrates the importance of developing a more sensitive, specific and cost-effective 11 approach. We discuss Other clinical and biomarker variables may have a role in predicting the risk of 12 non-sudden death and in the identification of those unlikely to benefit from ICD implantation. 13 
14
Stage of Disease, Co-morbidities and Competing Risks from Non-Sudden Causes of Death 15
It has long been recognized that patients with advanced HF are unlikely to benefit from ICD therapy 16 due to high rates of death from nonarrhythmic causes. This is reflected in guidelines that do not 17 recommend ICD implantation for patients with NYHA Class IV symptoms, unless cardiac transplant is 18 planned, or for those with a life expectancy < 1 year 12, 13 . The risk of death from non-sudden causes 19 is especially relevant in older patients and in those with more co-morbidities. In planned sub-group 20 analysis of the DANISH trial, patients aged >68 years of age had a trend towards increased mortality A large meta-analysis combined 45 studies, including 6,088 patients with non-ischemic DCM, in an 1 attempt to summarize existing data 31 . When available, arrhythmic end-points including SCD, 2 ventricular arrhythmia or appropriate ICD discharge were used; all-cause mortality was used as an 3 alternative when these were not available. Although inter-study reproducibility was poor for the 4 majority of variables, the authors concluded that the most promising for the prediction of adverse 5 events were QRS complex fragmentation (OR 6.73; 95% CI 3.85-11.76; p<0.001) and the presence of 6 MTWA (OR 4.66; 95% CI 2.55-8.53; p<0.001). The odds ratios for the majority of the remaining 7 parameters were between 1.5 and 3.0, suggesting lower predictive value ( Table 4) . 8
While the small number of studies limits the ability to interpret the predictive ability of QRS 9 fragmentation, a large number of studies support the potential of MTWA and a meta-analysis of 10 patients with non-ischemic DCM has corroborated the findings of Goldberger and colleagues 32 . A 11 study in a mixed ischemic and non-ischemic population has suggested that the presence of MTWA 12 may be a stronger predictor of arrhythmia when present in patients taking beta-blockers (patients 13 on beta-blockers: HR 5.39; 95% CI 2.68-10.84 p<0.001; entire population: HR 1.95; 95% CI 1.29-2.96; 14 p=0.002) 33 . Others have emphasized the negative predictive value of a negative MTWA test 34 ; 15 however, it should be noted that even a coin toss has a high negative predictive value when the 16 event rate is low 35 . Authors have proposed the use of MTWA testing to select patients with a LVEF 17 <35% who are unlikely to benefit from ICD implantation, but this has not been validated 36 . 18 
19
Echocardiography 20
Echocardiography is the first-line imaging investigation in the work-up of patients with DCM. Use of 21 echocardiography measurements to predict arrhythmic events is therefore an attractive concept. 22
The ability of global longitudinal strain and mechanical dispersion, a measure of mechanical 23 dyssynchrony, to predict sustained ventricular arrhythmia or SCD was investigated in 94 patients 24 with non-ischemic DCM over 22-months by Haugaa and colleagues 37 . They found that both measures non-ischemic DCM prior to primary prevention ICD implantation 38 . Longitudinal strain was 6 independently associated with the primary end-point of appropriate ICD therapy, albeit to a modest 7 degree (per % increase -HR 1.12; 95% CI 1.01-1.20; p=0.032). Importantly, however it appears 8 unlikely that functional techniques, such as strain measurement, will provide adequate 9 discrimination between the risk of SCD and death from HF. and production of reactive oxygen species 40 . The end result is the activation of myofibroblasts, the 22 production of collagen and myocyte cell death 39, 40 . 23
Fibrosis is thought to provide a substrate for ventricular arrhythmia. An electrical mapping study in 24 patients with DCM demonstrated that only those with replacement fibrosis, identified by lategadolinium-enhanced cardiovascular magnetic resonance imaging (LGE-CMR), had inducible VT or a 1 history of sustained VT 41 . Moreover, in patients with inducible VT, the major component was 2 mapped to the area of replacement fibrosis. Mapping studies have also linked the presence of 3 fibrosis with fractionated electrograms, slowed conduction and conduction block that have been 4 associated with VT and VF 42, 43 . The gray-zone between areas of fibrosis and surviving myocardium is 5 thought to act as the nidus for re-entry wavefronts in patients with IHD and similar mechanisms may 6 account for 80% of VT in DCM LGE-CMR imaging has demonstrated that replacement fibrosis occurs in around 30% of patients with 10
DCM. This frequently occurs in a linear mid-wall distribution and has been validated with histology 11 (Figure 2 ) 45, 46 . Multiple studies have demonstrated an association between mid-wall fibrosis (MWF) 12 on LGE-CMR imaging and SCD events in patients with DCM (Table 2) [45] [46] [47] [48] [49] [50] [51] [52] [53] . 13
The largest study followed 472 patients with non-ischemic DCM of all severities for a median of 5.3 14 years 45 . Similar to other studies, 30.0% of patients had MWF 48, 49 . There was also an association between the presence of MWF and HF events (HR 1.62; 95% CI 1.00-24 2.61; p=0.049), although this was notably weaker than that with SCD events. The addition of MWF toLVEF significantly improved risk re-classification for SCD/aborted SCD, with 29% of patients being 1 correctly re-classified after the addition of MWF to a model including LVEF. 2
Another study followed 162 non-ischemic DCM patients who underwent LGE-CMR imaging prior to 3 planned ICD implantation for a median of 29 months 47 . This selected cohort had a higher incidence 4 of MWF, occurring in 50.0%. Following adjustment, the presence and extent of MWF were the 5 strongest predictors of the primary end-point, which was a composite of cardiovascular death and Three large meta-analyses, including 1488, 1443, 2948 patients with non-ischemic DCM, confirmed 22 the above findings 48, 49, 53 . In the pooled analysis of Kuruvilla et 53 . 5
Interestingly, this association was observed in studies with a mean LVEF >35% (OR 5.2; 95% CI 3.4-6 7.9; p<0.001) and those with a mean LVEF <35% (OR 4.2; 95% CI 2.4-7.2; p<0.001). 7
A recent study performed exclusively in patients with non-ischemic DCM and a LVEF >40% suggests 8 that LGE-CMR imaging identifies patients with less severe left ventricular impairment at high-risk of 9 SCD. Those with MWF had significantly higher rates of SCD and aborted SCD (defined as an 10 appropriate ICD shock, a non-fatal episode of VF or VT causing hemodynamic compromise and 11 requiring cardioversion) compared with those without (HR 9.2; 95% CI 3.9-21.8; p<0.0001) and this 12 remained similar after adjusting for other prognostic variables (HR 9.3; 95% CI 3.9-22.3; p<0.0001) 54 . 13
The absolute event rate in patients with MWF was similar to that in patients with a LVEF <35% from 14 similar previous studies 45 . Importantly, the risk of death from competing causes in patients with 15 MWF and mild or moderate reductions in LVEF was low. However, further studies are needed to 16 establish whether patients with LVEF >35% and high-risk features benefit from ICD therapy 55 . 17
Although promising, there are currently no data from randomized studies confirming that patients 18 with MWF benefit from ICD implantation, and it remains unclear whether the addition of LGE to 19 LVEF will sufficiently improve risk stratification or whether additional variables will be required 56 . 20
Pending randomized studies, the presence or absence of MWF on LGE-CMR imaging may be used to 21 aid decision-making with regards to ICD implantation in borderline cases. Further work is required to 22 investigate the linearity of the relationship between the extent of MWF and SCD events, and 23
whether there are reproducible amounts of MWF that reliably predict hard adverse arrhythmic 24 events with the most accuracy. 61 . This 23 suggests that it may be possible to measure interstitial fibrosis non-invasively. Early work has 24 investigated the predictive value of T1-mapping in risk prediction 62, 63 . However, further studies are required to clarify whether one measure is superior to the other. The 10 crucial question is whether T1-mapping provides additional value to LGE, which already forms part 11 of a routine scan. 12 An alternative approach is the use of biomarkers of collagen turnover as a surrogate for myocardial 13 fibrosis 64 . Correlation between serum procollagen type I carboxy-terminal peptide (PICP) and fibrosis 14 on myocardial biopsy has been reported in hypertensive patients and an association between 15 galectin-3 and MWF on LGE-CMR in non-ischemic DCM patients has been demonstrated 65, 66 . Current 16 studies investigating collagen biomarkers are limited by small numbers of patients and outcome 17 events and therefore no conclusions can be drawn about their potential role in SCD risk 18 assessment 67 . More research is required. 19 
20
Cardiac MIBG imaging 21
Autonomic dysfunction has long been associated with ventricular arrhythmogenesis 68 . Variable 22 sympathetic activation of the myocardium results in heterogeneities in conduction velocities and 23 refractory periods, creating a pro-arrhythmic environment 69 . Although not part of routine practice, it 24 is possible to detect cardiac autonomic dysfunction using 123-metaiodobenzylguanidine (MIBG)scintigraphy. Parameters indicating autonomic dysfunction include elevated tracer washout rates, 1 abnormal ratio of uptake between the heart and mediastinum and large myocardial tracer defects. 2 Several studies have supported the ability of these parameters to predict SCD and adverse 3 arrhythmic events in patients with DCM and broader HF populations ( Table 3) [70] [71] [72] [73] [74] [75] . Merlet and 4 colleagues performed a study evaluating exclusively patients with non-ischemic DCM 70 . In 5 multivariable analysis, they found that radionuclide-determined LVEF (p=0.02) and low 6 heart:mediastinum (H:M) ratio (p<0.0001) predicted all-cause mortality while low H:M ratio 7 predicted SCD (p=0.0015). The AdreView Myocardial Imaging for Risk Evaluation in Heart Failure 8 (ADMIRE-HF) study demonstrated that in patients with ischemic and non-ischemic HF, a H:M ratio 9 ≥1.6 was associated with a lower risk of adverse arrhythmic events (defined as spontaneous 10 sustained VT, resuscitated cardiac arrest or appropriate ICD therapy including ATP; 3.5% vs 10.4%; 11 p<0.01) and a lower incidence of the primary composite end-point that included arrhythmic events, 12 NYHA progression and cardiovascular death (HR 0.36; 95% CI 0.17-0.75; p=0.006) 72 . Survival 13 modelling of patients without an ICD at enrollment demonstrated that H:M ratio added incremental 14 prognostic value and improved net re-classification, however it did not identify those who had 15 improved survival with ICD implantation 69, 76 . A sub-study of ADMIRE-HF assessed the value of 16 summed rest score on single photon emission computed tomography, a marker of myocardial scar, 17 in risk stratifying 317 patients with non-ischemic HF 71 . Overall, there were 22 arrhythmic events, 18 defined as appropriate ICD therapy (ATP or shock), resuscitated cardiac arrest and sustained VT, over 19 a median of 17 months. On univariable analysis, H:M ratio <1.6 and a summed rest score >8 were 20 associated with the end-point. Multivariable analysis performed in patients with a H:M ratio<1. 6 21 demonstrated that a summed rest score of >8 was the only independent predictor of the end-point. 22
These studies support the hypothesis linking autonomic dysfunction to increased rates of SCD. 23 Further larger studies confirming the findings in patients with DCM and the measurements with the 24 best sensitivity and specificity for the prediction of SCD are required. The diverse range of genes thought to cause DCM, encoding for a wide range of proteins with 25 different functions, not only adds to the challenges of variant interpretation but also creates them inthe search for new mutations 3 . The most common mutations occur in genes encoding sarcomeric 1 proteins and also in genes related to the nuclear envelope, the cytoskeleton and Z-band proteins. 2
With the growth in sequencing, the identification of rare variants that contribute to the disease 3 phenotype and carry adverse arrhythmic risk is becoming foreseeable. Considering that DCM is 4 often diagnosed late and occasionally at post-mortem, genetic screening enabling early diagnosis 5 and risk stratification is attractive. We discuss our understanding of the risk associated with specific 6 mutations and work aimed at identifying genetic modifiers of risk. replicated in other studies and supports the view that ICDs should be implanted earlier than current 21 guidelines recommend in these patients and in all those requiring pacemaker implantation 82, 83 . 22
Truncating mutations of the TTN gene, which encodes the giant titin protein, are thought to be the 23 most common causative mutations, occurring in 25% cases of FDCM, 18% of sporadic cases and <1% 24 of controls 84 . Two molecules of titin span the length of the sarcomere and act to generate andregulate contractile force 85 . Titin has an important role in modulating responses to insults and loads 1 and truncating mutations appear to result in susceptibility to developing contractile impairment 86 . 2
Herman and colleagues studied 312 patients with DCM and demonstrated similar rates of adverse 3 outcomes, in patients with truncating mutations in TTN compared to those without 87 . More recently, 4 Jansweijer, et al. demonstrated that DCM patients with truncating variants in TTN had a milder 5 phenotype of disease at baseline and higher rates of reverse remodelling compared with patients 6 with LMNA mutations and those without a variant identified 88 . This suggests that DCM related to 7 TTN may be a more treatable form. Larger studies investigating SCD end-points are required. 8
Studies in patients with other specific mutations have been smaller. A study in 436 men with DCM 9 identified dystrophin variants in 34 89 . Over 60 months, patients with dystrophin mutations had high 10 rates of HF events with 23% undergoing transplantation and 26% dying from HF. Conversely, 11 however, they demonstrated low incidences of major arrhythmic events with no patients suffering 12 SCD or life-threatening ventricular arrhythmia. Although small, this study suggests that patients with 13 dystrophin variants should be streamlined to advanced HF therapies rather than ICD implantation. 14 Merlo and colleagues studied 179 families with DCM and compared patients with rare sarcomeric 15 gene variants to genotype negative patients 90 . Overall, 52 patients had rare variants in TTN, MYH6, 16 MYH7, TNNT2 and MYBC and although these patients had a higher LVEF at baseline, after 50 years of 17 age, rates of adverse outcomes including ventricular arrhythmia, death and cardiac transplantation 18 were higher. Other studies have suggested that mutations in TNNT2, may predispose to ventricular 19 arrhythmias independent of structural changes and this may be mediated through alterations in 20 myocyte calcium sensitivity 91, 92 . A study has demonstrated reduced arrhythmic susceptibility in mice 21 with TNNT2 mutations treated with a calcium de-sensitizer 92 .
22
A founder mutation in the PLN gene, which encodes phospholamban, a protein with an important 23 role in calcium homeostasis, has been associated with profound arrhythmic tendencies in patients 24 with DCM and also those without structural phenotypes 93 . Van Rijsingen and colleagues studied 403carriers of a specific mutation in the PLN gene, 21% of whom met diagnostic criteria for DCM 93 . Over 1 42 months, 19% had malignant ventricular arrhythmia defined as SCD, resuscitated cardiac arrest or 2 appropriate ICD intervention. In patients with an LVEF <45%, the incidence of ventricular arrhythmia 3 rose to 39%. These studies suggest that mutations in genes controlling calcium handling, also known 4 to cause DCM, may influence arrhythmic risk independent of structural changes. This provides 5 opportunity for the development of therapeutics targeting specific mechanisms of 6 arrhythmogenesis. 7
Recently, truncating mutations in FLNC, a gene which encodes filamin, a protein that attaches 8 membrane proteins to the cystokeleton, have been associated with an arrhythmogenic phenotype, 9 similar to that observed with desmin mutations 94 . In 2,877 patients with inherited cardiovascular 10 disease, truncating mutations in FLNC were identified in 28 probands and 54 relatives 94 . Overall, 97% 11 of carriers over the age of 40 years had phenotypic evidence of the disease characterised by LV 12 dilatation, reduced LVEF and myocardial fibrosis. Twelve carriers suffered SCD during the study, 13 conducted over 3.5 years, and there was a history of SCD in 28 relatives of carriers without genetic 14 data. Altogether, 21 of 28 evaluated families had a history of SCD. This suggests that truncating 15 mutations in FLNC are associated with a high incidence of SCD. 16
In conclusion, large longitudinal studies investigating specific SCD-focused end-points in patients 17 with DCM and specific rare variants are required to better inform decision-making. Currently, it 18 appears that, in addition to carriers of LMNA mutations, carriers of a specific PLN or truncating FLNC 19 mutations should be stratified at higher risk of SCD. 20 
21
Genome Wide Association Studies -DCM and SCD Risk 22 Given the variable penetrance and expressivity seen in DCM, the importance of genetic (and 23 environmental) modifiers has widely been accepted. Genetic susceptibility to SCD has also been 24 recognized with the incidence of VF in patients having an acute myocardial infarction stronglyassociated with a family history of SCD, independently of other traditional IHD disease parameters 77 . 1
Based on these observations, genome wide association studies (GWAS) have attempted to identify 2 novel susceptibility loci that modify an individual's risk of developing DCM and suffering SCD. These 3 types of studies mostly identify single nucleotide polymorphisms (SNPs) in non-coding DNA that are 4 thought to affect gene expression. 5
A small number of loci associated with the development of DCM have been reported 95 . These 6 include a SNP within the major histocompatibility complex on chromosome 6, which has also been 7 linked to inflammatory diseases such as psoriasis 95 . The authors use this to support the hypothesis 8 that a genetically-driven inflammatory mechanism underlies the disease in some patients. 9
GWAS performed in large populations of SCD patients have identified several potential loci that are 10 associated with an individual's risk, albeit to a modest extent [96] [97] [98] . Perhaps the most promising are 11 those associated with the BAZ2B and CXADR genes, the latter of which has been linked with the 12 development of DCM and myocarditis 96, 98 . Other groups have identified SNPs that modify electrical 13 parameters, such as QRS and QT intervals, known as endophenotypes, which are known to influence 14 arrhythmic risk 99 . Genetic variants known to modify endophenotypes have been linked with 15 increased arrhythmic risk in other diseases and may have similar effects in DCM 99 . 16
In summary, the scope of genetics to identify common variants that may modify SCD risk is great. 17
However, advanced work in coronary disease has emphasized the small incremental value of each 18 variant in isolation, and the possible need for the effects of even hundreds of variants to be 19 combined into a model to provide a clinically useful estimation of risk in a heterogeneous disease 100 . 20
Conclusion 22
Existing guidelines lack sensitivity and specificity for the selection of patients with DCM for primary 23 prevention ICD implantation. These require refinement to produce a more personalized and preciseidentify patients at particularly high-risk of death from competing causes, who are unlikely to benefit 1 from ICD therapy, will form an important part of this process. There is growing evidence that 2 characteristics, other than LVEF, may be used to identify those at increased risk of SCD. Considering 3 the multifactorial basis of ventricular arrhythmogenesis in DCM, it appears likely that an algorithm 4 including multiple tests, which detect different pathophysiological processes involved in arrhythmia 5 generation, may be required. LGE-CMR imaging is a routinely employed technique in the 6 investigation of DCM, while MTWA analysis is an inexpensive additional test that is relatively simple 7 to perform. Nuclear imaging to detect autonomic dysfunction is promising, however its use within 8 clinical practice must increase. Although a great deal of work is needed to integrate genetic risk 9 prediction into clinical practice, we believe the identification of high-risk rare variants, in addition to 10 LMNA, will play an increasing role. 11
Assimilating our current understanding, we have proposed an algorithm, based on current evidence 12 ( Figure 4A ) to consider for risk stratification of patients with DCM, and a further template that may 13 be used in the future ( Figure 4B ). Where randomized trials investigating the effects of ICD 14 implantation are unavailable, such as in patients identified to have a high-risk of SCD with a LVEF 15 >35%, we have taken a pragmatic approach recommending evaluation on a case-by-case basis in a 16 multidisciplinary setting. Multi-center, prospective registries incorporating CMR imaging, genetic, 17 biomarker and electrophysiological data in unselected DCM cohorts should be the next step in the 18 pursuit of improved risk stratification, with the aim of creating a multivariable risk score with 19 improved discrimination. Predicted annual risks of SCD and non-sudden death at which patients are 20 most likely to gain cost-effective benefit from ICD therapy may be confirmed taking into account 21 pre-existing clinical trial data. This should be followed by randomized trials investigating the effects 22 of interventions, including ICD implantation, in patients deemed to be at high-risk of SCD and 23
without an excessive risk of death from competing causes. 24 Halliday et al; DCM risk stratification; V2 
